Menarini Stemline licenses Georgiamune GIM-621 oral cancer immunotherapy in deal worth up to $1.1 billion
Menarini's Stemline Therapeutics has secured worldwide rights to Georgiamune's investigational oral cancer immunotherapy GIM-621 in a licensing agreement worth up to $1.1 billion.
The exclusive collaboration gives Stemline global development, manufacturing and commercialisation rights to GIM-621, a preclinical first-in-class oral small-molecule immunotherapy being investigated for multiple solid tumours.
Georgiamune will receive $45 million in combined upfront and near-term payments and may earn additional preclinical, development, regulatory and commercial milestones, bringing potential consideration to $1.1 billion plus royalties.
Field | Content |
Article Type | Deals |
Companies | Menarini Group; Stemline Therapeutics; Georgiamune |
Deal Type | Exclusive worldwide licensing and collaboration agreement |
Licensor | Georgiamune |
Licensee | Stemline Therapeutics, a Menarini Group company |
Licensed Asset | GIM-621 |
Therapeutic Area | Oncology |
Target Indications | Multiple solid tumours under investigation |
Therapeutic Modality | Oral small-molecule immunotherapy |
Asset Description | Investigational first-in-class oral immuno-oncology agent |
Development Stage | Preclinical |
Licensed Rights | Global development, manufacturing and commercialisation |
Territory | Worldwide |
Upfront and Near-Term Payments | $45 million combined; individual amounts not disclosed |
Total Potential Deal Value | Up to $1.1 billion plus royalties |
Additional Milestones | Preclinical, development, regulatory and commercial milestones; individual amounts not disclosed |
Royalties | Additional royalties; rates not disclosed |
Announcement Date | 22 October 2026 |
What Happened | Menarini subsidiary Stemline Therapeutics entered an exclusive global licensing and collaboration agreement for Georgiamune's GIM-621. |
Why It Matters | The transaction adds a novel investigational oral immunotherapy programme to Menarini's oncology pipeline and provides Georgiamune with funding and potential downstream payments. |
Strategic Rationale | Stemline gains worldwide rights to advance GIM-621 while Georgiamune benefits from a pharmaceutical development and commercialisation partner. |
Key Takeaway | The agreement carries up to $1.1 billion in potential consideration plus royalties, but GIM-621 remains preclinical and most payments depend on future milestones. |
What to Watch | Preclinical validation, investigational new drug preparation, first-in-human development, target indications and milestone achievements. |
Primary Source | Menarini Group |
Primary Source URL | https://www.menarini.com/en-us/news/news-detail/georgiamune-and-menarini-group-enter-exclusive-global-license-and-collaboration-agreement-for-gim-621-a-first-in-class-oral-immuno-oncology-agent.html |
Relevant Date | 22 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare